Stem Cell Therapy Market Size At Around US$ 31.41 Bn In 2030

The stem cell therapy market would grow at a CAGR of 13.73% over the predicted time frame. The market is expected to increase in value from US$ 11.22 Bn in 2022 to US$ 31.41 Bn in 2030.

The on stem cell therapy Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.

Download Free Sample@ https://www.precedenceresearch.com/sample/1989

Report Scope of the Stem Cell Therapy Market

Report Coverage	Details
Market Size in 2022	USD 11.22 Billion
Market Size by 2030	USD 31.41 Billion
Growth Rate from 2022 to 2030	CAGR of 13.73%
Base Year	2021
Forecast Period	2022 to 2030
Segments Covered	Product, Therapy Type, Application, Technology, End User, Geography

A recent report provides crucial insights along with application based and forecast information in the Global Stem cell therapy Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Stem cell therapy market.

A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.

Companies and Manufacturers Covered

The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global Stem cell therapy market are included as given below:

Stem cell therapy Market Key Players

• Caladrius
• CELGENE CORPORATION
• ReNeuron Group plc
• Virgin Health Bank
• Opexa Therapeutics, Inc.
• Pluristem Therapeutics Inc
• STEMCELL Technologies Inc.
• Biovault family
• Precious Cells International Ltd
• Mesoblast Ltd
• Seneca Biopharmaceuticals, Inc.

Market Segments

By Product

• Adult Stem Cells (ASCs)
  • Hematopoietic
  • Mesenchymal
  • Neural
  • Epithelial/Skin
  • Others
• Human Embryonic Stem Cells (HESCs)
• Induced Pluripotent Stem Cells (iPSCs)
• Very Small Embryonic Like Stem Cells

By Therapy Type

• Autologous
• Allergenic

By Application

• Regenerative Medicine
  • Neurology
  • Orthopedics
  • Oncology
  • Hematology
  • Cardiovascular and Myocardial Infraction
  • Injuries
  • Diabetes
  • Liver Disorder
  • Incontinence
  • Others
• Drug Discovery and Development

By Technology

• Cell Acquiition
  • Bone Marrow Harvest
  • Umbilical Blood Cord
  • Apheresis
• Cell Production
  • Therapeutic Cloning
  • In-vitro Fertilization
  • Cell Culture
  • Isolation
• Cryopreservation
• Expansion and Sub-Culture

By End User

• Hospitals
• Research institutes
• surgical institutes
• Orders

By Geography

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • France
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Malaysia
  • Philippines
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC
  • North Africa
  • South Africa
  • Rest of the Middle East & Africa

Report Objectives

• To define, describe, and forecast the global stem cell therapy market based on product, and region
• To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
• To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
• To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
• To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
• To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
• To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the stem cell therapy market

Table of Content

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Stem Cell Therapy Market 

5.1. COVID-19 Landscape: Stem Cell Therapy Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Stem Cell Therapy Market, By Product

8.1. Stem Cell Therapy Market, by Product, 2022-2030

8.1.1. Adult Stem Cells (ASCs)

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Human Embryonic Stem Cells (HESCs)

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Induced Pluripotent Stem Cells (iPSCs)

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Very Small Embryonic Like Stem Cells

8.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Stem Cell Therapy Market, By Therapy Type

9.1. Stem Cell Therapy Market, by Therapy Type, 2022-2030

9.1.1. Autologous

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Allergenic

9.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Stem Cell Therapy Market, By Application 

10.1. Stem Cell Therapy Market, by Application, 2022-2030

10.1.1. Regenerative Medicine

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Drug Discovery and Development

10.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Stem Cell Therapy Market, By Technology

11.1. Stem Cell Therapy Market, by Technology, 2022-2030

11.1.1. Cell Acquiition

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Cell Production

11.1.2.1. Market Revenue and Forecast (2017-2030)

11.1.3. Cryopreservation

11.1.3.1. Market Revenue and Forecast (2017-2030)

11.1.4. Expansion and Sub-Culture

11.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Stem Cell Therapy Market, By End User

12.1. Stem Cell Therapy Market, by End User, 2022-2030

12.1.1. Hospitals

12.1.1.1. Market Revenue and Forecast (2017-2030)

12.1.2. Research institutes

12.1.2.1. Market Revenue and Forecast (2017-2030)

12.1.3. surgical institutes

12.1.3.1. Market Revenue and Forecast (2017-2030)

12.1.4. Orders

12.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 13. Global Stem Cell Therapy Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Product (2017-2030)

13.1.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

13.1.3. Market Revenue and Forecast, by Application (2017-2030)

13.1.4. Market Revenue and Forecast, by Technology (2017-2030)

13.1.5. Market Revenue and Forecast, by End User (2017-2030)

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Product (2017-2030)

13.1.6.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

13.1.6.3. Market Revenue and Forecast, by Application (2017-2030)

13.1.6.4. Market Revenue and Forecast, by Technology (2017-2030)

13.1.6.5. Market Revenue and Forecast, by End User (2017-2030)

13.1.7.  Rest of North America

13.1.7.1.  Market Revenue and Forecast, by Product (2017-2030)

13.1.7.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

13.1.7.3. Market Revenue and Forecast, by Application (2017-2030)

13.1.7.4. Market Revenue and Forecast, by Technology (2017-2030)

13.1.7.5. Market Revenue and Forecast, by End User (2017-2030)

13.2. Europe

13.2.1. Market Revenue and Forecast, by Product (2017-2030)

13.2.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

13.2.3. Market Revenue and Forecast, by Application (2017-2030)

13.2.4. Market Revenue and Forecast, by Technology (2017-2030)

13.2.5. Market Revenue and Forecast, by End User (2017-2030)

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Product (2017-2030)

13.2.6.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

13.2.6.3. Market Revenue and Forecast, by Application (2017-2030)

13.2.6.4. Market Revenue and Forecast, by Technology (2017-2030)

13.2.6.5. Market Revenue and Forecast, by End User (2017-2030)

13.2.7.  Germany

13.2.7.1. Market Revenue and Forecast, by Product (2017-2030)

13.2.7.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

13.2.7.3.  Market Revenue and Forecast, by Application (2017-2030)

13.2.7.4. Market Revenue and Forecast, by Technology (2017-2030)

13.2.7.5. Market Revenue and Forecast, by End User (2017-2030)

13.2.8.  France

13.2.8.1. Market Revenue and Forecast, by Product (2017-2030)

13.2.8.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

13.2.8.3. Market Revenue and Forecast, by Application (2017-2030)

13.2.8.4. Market Revenue and Forecast, by Technology (2017-2030)

13.2.8.5.  Market Revenue and Forecast, by End User (2017-2030)

13.2.9. Rest of Europe

13.2.9.1. Market Revenue and Forecast, by Product (2017-2030)

13.2.9.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

13.2.9.3. Market Revenue and Forecast, by Application (2017-2030)

13.2.9.4. Market Revenue and Forecast, by Technology (2017-2030)

13.2.9.5.  Market Revenue and Forecast, by End User (2017-2030)

13.3. APAC

13.3.1. Market Revenue and Forecast, by Product (2017-2030)

13.3.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

13.3.3. Market Revenue and Forecast, by Application (2017-2030)

13.3.4. Market Revenue and Forecast, by Technology (2017-2030)

13.3.5. Market Revenue and Forecast, by End User (2017-2030)

13.3.6.  India

13.3.6.1. Market Revenue and Forecast, by Product (2017-2030)

13.3.6.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

13.3.6.3. Market Revenue and Forecast, by Application (2017-2030)

13.3.6.4. Market Revenue and Forecast, by Technology (2017-2030)

13.3.6.5. Market Revenue and Forecast, by End User (2017-2030)

13.3.7. China

13.3.7.1. Market Revenue and Forecast, by Product (2017-2030)

13.3.7.2.  Market Revenue and Forecast, by Therapy Type (2017-2030)

13.3.7.3. Market Revenue and Forecast, by Application (2017-2030)

13.3.7.4. Market Revenue and Forecast, by Technology (2017-2030)

13.3.7.5. Market Revenue and Forecast, by End User (2017-2030)

13.3.8. Japan

13.3.8.1. Market Revenue and Forecast, by Product (2017-2030)

13.3.8.2.  Market Revenue and Forecast, by Therapy Type (2017-2030)

13.3.8.3. Market Revenue and Forecast, by Application (2017-2030)

13.3.8.4. Market Revenue and Forecast, by Technology (2017-2030)

13.3.8.5. Market Revenue and Forecast, by End User (2017-2030)

13.3.9. Rest of APAC

13.3.9.1. Market Revenue and Forecast, by Product (2017-2030)

13.3.9.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

13.3.9.3. Market Revenue and Forecast, by Application (2017-2030)

13.3.9.4. Market Revenue and Forecast, by Technology (2017-2030)

13.3.9.5. Market Revenue and Forecast, by End User (2017-2030)

13.4. MEA

13.4.1. Market Revenue and Forecast, by Product (2017-2030)

13.4.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

13.4.3. Market Revenue and Forecast, by Application (2017-2030)

13.4.4. Market Revenue and Forecast, by Technology (2017-2030)

13.4.5. Market Revenue and Forecast, by End User (2017-2030)

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Product (2017-2030)

13.4.6.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

13.4.6.3.  Market Revenue and Forecast, by Application (2017-2030)

13.4.6.4. Market Revenue and Forecast, by Technology (2017-2030)

13.4.6.5. Market Revenue and Forecast, by End User (2017-2030)

13.4.7. North Africa

13.4.7.1. Market Revenue and Forecast, by Product (2017-2030)

13.4.7.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

13.4.7.3. Market Revenue and Forecast, by Application (2017-2030)

13.4.7.4. Market Revenue and Forecast, by Technology (2017-2030)

13.4.7.5. Market Revenue and Forecast, by End User (2017-2030)

13.4.8. South Africa

13.4.8.1. Market Revenue and Forecast, by Product (2017-2030)

13.4.8.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

13.4.8.3. Market Revenue and Forecast, by Application (2017-2030)

13.4.8.4. Market Revenue and Forecast, by Technology (2017-2030)

13.4.8.5. Market Revenue and Forecast, by End User (2017-2030)

13.4.9. Rest of MEA

13.4.9.1. Market Revenue and Forecast, by Product (2017-2030)

13.4.9.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

13.4.9.3. Market Revenue and Forecast, by Application (2017-2030)

13.4.9.4. Market Revenue and Forecast, by Technology (2017-2030)

13.4.9.5. Market Revenue and Forecast, by End User (2017-2030)

13.5.  Latin America

13.5.1. Market Revenue and Forecast, by Product (2017-2030)

13.5.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

13.5.3. Market Revenue and Forecast, by Application (2017-2030)

13.5.4. Market Revenue and Forecast, by Technology (2017-2030)

13.5.5. Market Revenue and Forecast, by End User (2017-2030)

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Product (2017-2030)

13.5.6.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

13.5.6.3. Market Revenue and Forecast, by Application (2017-2030)

13.5.6.4. Market Revenue and Forecast, by Technology (2017-2030)

13.5.6.5. Market Revenue and Forecast, by End User (2017-2030)

13.5.7. Rest of LATAM

13.5.7.1. Market Revenue and Forecast, by Product (2017-2030)

13.5.7.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

13.5.7.3. Market Revenue and Forecast, by Application (2017-2030)

13.5.7.4. Market Revenue and Forecast, by Technology (2017-2030)

13.5.7.5. Market Revenue and Forecast, by End User (2017-2030)

Chapter 14. Company Profiles

14.1. Caladrius

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. CELGENE CORPORATION

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. ReNeuron Group plc

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Virgin Health Bank

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Opexa Therapeutics, Inc

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Pluristem Therapeutics Inc

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. STEMCELL Technologies Inc.

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Biovault family

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Precious Cells International Ltd

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Mesoblast Ltd

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 774 402 6168

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com

 Blog: https://www.pharma-geek.com